why sirolimus debs could offer benefits over paclitaxel dcbs (europcr 2020)
Published 3 years ago • 39 plays • Length 2:16Download video MP4
Download video MP3
Similar videos
-
3:25
addressing unmet clinical needs with sirolimus debs (europcr 2020)
-
53:13
sirolimus-coated balloons, an appraisal on its potential advantages over paclitaxel - europcr 2020
-
26:48
overcoming the limitations of paclitaxel - sirolimus coated balloon for the treatment of pvd
-
9:35
crt 2022 - what are the challenges for sirolimus coated balloons - dr. aloke finn
-
1:01:46
is sirolimus emerging as a potential future treatment strategy inpad over paclitaxel?
-
9:53
sirolimus-coated balloon a “clear alternative” to paclitaxel-coated balloons
-
59:14
paclitaxel and sirolimus coated balloons: create evidence before claims - europcr 2021
-
1:10:55
experiences, tips and tricks with magictouch - sirolimus coated balloon
-
3:13
pharmaledger's detecting falsified medicines use case
-
1:19:31
beginning with the end in mind - ffr vs. ivus imaging - aict-asiapcr 2022
-
42:33
sirolimus coated balloon: expanding the scope of cad treatment - aict-asiapcr 2022
-
22:39
debs in complex pcis episode 1 – sustained limus release in a nutshell presented by john shulze
-
1:06:14
dcb coronary - paclitaxel vs sirolimus, dr. bruno scheller
-
8:41
paclitaxel drug coated technology vs sirolimus coated technology for infra popliteal disease lawrenc
-
14:29
crt 2022 a novel sirolimus-eluting balloon - dr. aloke finn
-
51:14
redefining indications for drug-eluting balloons in complex pci - europcr 2022
-
1:53:20
the pros & cons in the use of debs in complex pcis - our experience with the latest technologies
-
14:48
pilot study of sirolimus coated balloon | dasy 2020 | concept medical
-
7:57
the future of drug-coated balloon technology - europcr 2019
-
0:53
korea's biosimilar drug market to nearly double by 2019
-
3:07
sirolimus has “a much wider” safety window and shows fewer local effects than paclitaxel